HBV+DEN-treated Il33KO, ST2KO, and Irf3KO mice showed significantly lower liver tumor burden and decreased PCNA+ proliferating hepatocytes compared with HBV+DEN-treated WT mice at 8 months post-infection (Fig. 3a–d and Supplementary Fig. 4a). The gene discussed is PCNA; the disease is infection.